Review



egfr-activating mutations  (MedGenome)

 
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 90
      Buy from Supplier

    Structured Review

    MedGenome egfr-activating mutations
    Egfr Activating Mutations, supplied by MedGenome, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/egfr-activating+mutations/egfr+activating+mutations/pm40414381-144-18-6
    Average 90 stars, based on 1 article reviews
    egfr-activating mutations - by Bioz Stars, 2026-09
    90/100 stars

    Images

    Related Articles

    other:

    Article Title: An allele-specific quantitative PCR strategy for detection of EGFR T790M mutations by liquid biopsy in non-small cell lung cancer patients.
    Article Snippet: From the lab reports obtained from MedGenome Labs Ltd., India, using convenient blood or tissue samples from patients, EGFR-activating mutations were present in all patients, with EGFR exon 21 L858R mutation in 10 patients (29.4 %) and EGFR exon 19 deletion mutation in 24 patients (70.6 %).



    Similar Products

    egfr activating mutations  (Vitro Biopharma Inc)
    86
    Vitro Biopharma Inc egfr activating mutations
    Egfr Activating Mutations, supplied by Vitro Biopharma Inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/egfr-activating+mutations/activating+egfr+mutations/fda_document____drugsatfda_docs_slash_nda_slash_2013_slash_201292orig1s000medr-107-26-8
    Average 86 stars, based on 1 article reviews
    egfr activating mutations - by Bioz Stars, 2026-09
    86/100 stars
    		  Buy from Supplier
    egfr-activating mutations  (MedGenome)
    90
    MedGenome egfr-activating mutations
    Egfr Activating Mutations, supplied by MedGenome, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/egfr-activating+mutations/egfr+activating+mutations/pm40414381-144-18-6
    Average 90 stars, based on 1 article reviews
    egfr-activating mutations - by Bioz Stars, 2026-09
    90/100 stars
    		  Buy from Supplier
    adenocarcinomas specimens from patients’ surgically resected tumors (srt) with egfr activating mutations (#7, #11)  (Charles River Laboratories)
    90
    Charles River Laboratories adenocarcinomas specimens from patients’ surgically resected tumors (srt) with egfr activating mutations (#7, #11)
    Validation of R-index in mice model and patients (A and B) R-index changes in mice between treatment-naive and osimertinib or Erlotinib treatment in-vivo . <t>SRT,</t> surgically resected tumors; PDX, patient-derived xenografts. (C) Changes of R-index and prognosis of patients pro- and <t>post</t> <t>EGFR-TKI</t> treatment. (D) Correlation plot of R-index and PFS. (E) Correlation of R-index and prognosis of patients’ pro- and post EGFR-TKI treatment and the median R-index is used to divide high and low drug resistance groups. (F) Correlation plot of R-index and PFS.
    Adenocarcinomas Specimens From Patients’ Surgically Resected Tumors (Srt) With Egfr Activating Mutations (#7, #11), supplied by Charles River Laboratories, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/egfr-activating+mutations/adenocarcinomas+specimens+from+patients%E2%80%99+surgically+resected+tumors++srt++with+egfr+activating+mutations+++7+++11+/pmc10241979-90-42-61
    Average 90 stars, based on 1 article reviews
    adenocarcinomas specimens from patients’ surgically resected tumors (srt) with egfr activating mutations (#7, #11) - by Bioz Stars, 2026-09
    90/100 stars
    		  Buy from Supplier
    osimertinib is an irreversible, central nervous system (cns) active egfr-tki, selective for both egfrm and t790m resistance mutations.  (AstraZeneca ltd)
    90
    AstraZeneca ltd osimertinib is an irreversible, central nervous system (cns) active egfr-tki, selective for both egfrm and t790m resistance mutations.
    Validation of R-index in mice model and patients (A and B) R-index changes in mice between treatment-naive and osimertinib or Erlotinib treatment in-vivo . <t>SRT,</t> surgically resected tumors; PDX, patient-derived xenografts. (C) Changes of R-index and prognosis of patients pro- and <t>post</t> <t>EGFR-TKI</t> treatment. (D) Correlation plot of R-index and PFS. (E) Correlation of R-index and prognosis of patients’ pro- and post EGFR-TKI treatment and the median R-index is used to divide high and low drug resistance groups. (F) Correlation plot of R-index and PFS.
    Osimertinib Is An Irreversible, Central Nervous System (Cns) Active Egfr Tki, Selective For Both Egfrm And T790m Resistance Mutations., supplied by AstraZeneca ltd, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/egfr-activating+mutations/azd9291/10__1016_slash_j__jtho__2018__08__667-95-100-79
    Average 90 stars, based on 1 article reviews
    osimertinib is an irreversible, central nervous system (cns) active egfr-tki, selective for both egfrm and t790m resistance mutations. - by Bioz Stars, 2026-09
    90/100 stars
    		  Buy from Supplier

    Image Search Results


    Validation of R-index in mice model and patients (A and B) R-index changes in mice between treatment-naive and osimertinib or Erlotinib treatment in-vivo . SRT, surgically resected tumors; PDX, patient-derived xenografts. (C) Changes of R-index and prognosis of patients pro- and post EGFR-TKI treatment. (D) Correlation plot of R-index and PFS. (E) Correlation of R-index and prognosis of patients’ pro- and post EGFR-TKI treatment and the median R-index is used to divide high and low drug resistance groups. (F) Correlation plot of R-index and PFS.

    Journal: iScience

    Article Title: Stratification of non-small cell lung adenocarcinoma patients with EGFR actionable mutations based on drug-resistant stem cell genes

    doi: 10.1016/j.isci.2023.106584

    Figure Lengend Snippet: Validation of R-index in mice model and patients (A and B) R-index changes in mice between treatment-naive and osimertinib or Erlotinib treatment in-vivo . SRT, surgically resected tumors; PDX, patient-derived xenografts. (C) Changes of R-index and prognosis of patients pro- and post EGFR-TKI treatment. (D) Correlation plot of R-index and PFS. (E) Correlation of R-index and prognosis of patients’ pro- and post EGFR-TKI treatment and the median R-index is used to divide high and low drug resistance groups. (F) Correlation plot of R-index and PFS.

    Article Snippet: Because the cells in culture lacked in-vivo interactions, we applied R-index to investigate the response of mice to EGFR-TKIs treatment from xenograft data., Patient-derived xenograft (PDX) models were built by implanting small pieces (3–5 mm) of adenocarcinomas specimens from patients’ surgically resected tumors (SRT) with EGFR activating mutations (#7, #11) into the subcutaneous flank tissue of female SHO mice (Crlj: SHO-PrkdcscidHrhr, Charles River).

    Techniques: Biomarker Discovery, In Vivo, Derivative Assay